GILD

El interés en corto de Gilead Sciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Gilead Sciences. Los datos de interés en corto se actualizan cada dos semanas.

Gilead Sciences (NASDAQ:GILD) Bolsa, Informe de interés en corto

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

GILEAD SCIENCES ORD

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and maintains $75 price target.

News

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $75 Price Target

On Saturday, Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Merck &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed new results from a Phase 2 clinical study evaluating the investigational combination of <a target="_blank" href="https://www.benzinga.com//node/41416883" rel="noreferrer noopener">islatravir and lenacapavir</a>.
The data was presented at&nbsp;the ID&nbsp;Week 2024.
At 48 weeks, the investigational combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA &lt;50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39435880/gilead-sciences-faces-wall-street-speculation-about-obesity-drugs-despite-focus-on-liver-treatmen" rel="noreferrer noopener">Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments</a>.
Zero participants had a viral load of ≥50 copies/mL at Week 48.
In this open-label, active-controlled study, virologically suppressed adults (n=104) on Biktarvy&nbsp;(bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a week (n=52) or to continue daily oral Biktarvy (n=52).
The proportion of individuals with HIV-1 RNA &lt;50 c/mL at Week 48 by FDA snapshot algorithm (a secondary endpoint) showed that participants who switched to treatment with once-weekly islatravir and lenacapavir (ISL + LEN) or continued Biktarvy maintained comparable high rates of HIV suppression at Week 48 (94.2% v. 92.3%, respectively).
No participants treated with ISL + LEN or Biktarvy had a viral load of ≥ 50 copies/mL at Week 48 (another secondary endpoint).
19.2% of participants (n=10/52) in the ISL + LEN group experienced treatment-related adverse events (TRAEs), and the most common were dry mouth (n=2/52; 3.8%) and nausea (n=2/52; 3.8%).
TRAEs were reported by 5.8% of participants in the Biktarvy group (n=3/52).
No grade 3 or 4 TRAEs related to the study drug were reported in either treatment group.
In March, the companies&nbsp;released 24-week data from the Phase 2 study of the combination of islatravir and lenacapavir&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37521576/promising-hiv-treatment-phase-2-clinical-trial-success-for-gileads-and-mercks-combo-therapy" rel="noreferrer noopener">for HIV infection</a>.&nbsp;
At 24 weeks, the investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA &lt;50 copies/mL), which is a secondary endpoint of the study.&nbsp;
Price Action: GILD stock was down 0.59% at $86.21, and MRK is down 1.19% at $107.25 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41433662/nvidia-partners-with-startup-aidoc-to-accelerate-healthcare-ai-adoption" target="_blank" rel="noreferrer noopener">Nvidia Partners With Startup Aidoc To Accelerate Healthcare AI Adoption</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Susquehanna raised Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $70 to $80. Susquehanna analyst Christopher Rolland maintained a Positive rating. Lumentum shares closed at $66.23 on Friday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays boosted the price target for PPL Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) from $30 to $34. Barclays analyst Nicholas Campanella maintained an Equal-Weight rating. PPL shares closed at $32.66 on Friday. <a href="https://www.benzinga.com/quote/PPL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised the price target for monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from $300 to $340. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Webster Financial shares closed at $287.31 on Friday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Sportradar Group AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) price target from $12 to $15. JP Morgan analyst Samuel Nielsen upgraded the stock from Neutral to Overweight. Sportradar shares settled at $12.39 on Friday. <a href="https://www.benzinga.com/quote/SRAD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners boosted Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) price target from $74 to $96. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Gilead Sciences shares closed at $86.72 on Friday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein cut ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) price target from $1,052 to $815. Bernstein analyst Sara Russo maintained an Outperform rating. ASML shares closed at $723.26 on Friday. <a href="https://www.benzinga.com/quote/ASML/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from $94 to $104. Baird analyst Timothy Wojs maintained a Neutral rating. Stanley Black &amp; Decker shares settled at $106.40 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc raised Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) price target from $25 to $30. Keybanc analyst Alex Markgraff maintained an Overweight rating. Robinhood shares closed at $26.83 on Friday. <a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from $450 to $472. JP Morgan analyst Christopher Horvers maintained an Overweight rating. Ulta Beauty shares closed at $368.92 on Friday. <a href="https://www.benzinga.com/quote/ULTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) price target from $63 to $61. Barclays analyst David Anderson maintained an Overweight rating. SLB shares closed at $41.92 on Thursday. <a href="https://www.benzinga.com/quote/SLB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="498" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21092227/image-184-1024x498.png" alt="" class="wp-image-605244" style="width:518px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21092227/image-184-1024x498.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21092227/image-184-300x146.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21092227/image-184-768x374.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21092227/image-184.png 1338w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

Markets

ASML

HOOD

LITE

MNDY

SRAD

ULTA

Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 10.63% since its last report. The company recently reported that it has 17.74 million shares sold short, which is 1.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729516518_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Gilead Sciences's Recent Short Interest

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Mike Cikos upgraded the rating for GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) from Hold to Buy and announced a $70 price target. GitLab shares closed at $55.34 on Friday. <a href="https://www.benzinga.com/quote/GTLB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Andrew Berens upgraded Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Market Perform to Outperform and lifted the price target from $74 to $96. Gilead Sciences shares closed at $86.72 on Friday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Rob Sanderson upgraded the rating for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) from Hold to Buy but lowered the price target from $49 to $48. JD.com shares closed at $38.85 on Friday. <a href="https://www.benzinga.com/quote/JD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Timothy Wojs upgraded Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) from Neutral to Overweight and raised the price target from $160 to $196. Mohawk Industries shares closed at $161.05 on Thursday. <a href="https://www.benzinga.com/quote/MHK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Brooke Roach upgraded the rating for Warby Parker Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) from Neutral to Buy and raised the price target from $15 to $18. Warby Parker shares closed at $16.55 on Friday. <a href="https://www.benzinga.com/quote/WRBY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying JD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21082422/image-182-1024x489.png" alt="" class="wp-image-605089" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21082422/image-182-1024x489.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21082422/image-182-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21082422/image-182-768x367.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/21082422/image-182.png 1336w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

Upgrades

GTLB

WRBY

This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

In the latest quarter, 15 analysts provided ratings for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $84.87, a high estimate of $105.00, and a low estimate of $70.00. Witnessing a positive shift, the current average has risen by 8.81% from the previous average price target of $78.00.
<img src="https://www.benzinga.com/files/images/story/2024/1729512054_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Gilead Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>About Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences: Delving into Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of 5.36% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Gilead Sciences's net margin is impressive, surpassing industry averages. With a net margin of 23.21%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.01% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.28.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Gilead Sciences: Insights From 15 Financial Analysts

Leerink Partners analyst Andrew Berens upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Market Perform to Outperform and raises the price target from $74 to $96.

Leerink Partners Upgrades Gilead Sciences to Outperform, Raises Price Target to $96

At 48 weeks, the novel investigational combination maintained a high rate (n=49;&nbsp;94.2%) of viral suppression (HIV-1 RNA &lt;50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study. Zero participants had a viral load of &ge;50 copies/mL at Week 48. Week 24 results, including the study&#39;s primary endpoint, were previously&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2Fnews%2Fnews-details%2F2024%2Fgilead-and-merck-announce-phase-2-data-showing-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-at-week-24&amp;esheet=54138416&amp;newsitemid=20241019252729&amp;lan=en-US&amp;anchor=presented&amp;index=2&amp;md5=0c81558056064d58c7905363c74686f9">presented</a>&nbsp;at the 31st Conference on Retroviruses and Opportunistic Infections (CROI).

Reported Saturday, Gilead And Merck's Islatravir-Lenacapavir Combo Demonstrates High Efficacy In Weekly HIV Treatment At Week 48 In Phase 2 Study

On Friday, Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40988983/gilead-sciences-recalls-one-lot-of-its-covid-19-treatment-due-to-presence-of-glass-particles" rel="noreferrer noopener">Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles</a>.
The <a target="_blank" href="https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer" rel="noreferrer noopener">decision</a> was made in consultation with the FDA and does not affect the other approved Trodelvy indications within or outside the U.S.
Trodelvy was granted accelerated approval for metastatic urothelial cancer in 2021 based on tumor response rate and duration of response data from the global Phase 2, single-arm TROPHY-U-01 study.
Continued approval for this indication was contingent on verification and description of clinical benefit in the confirmatory TROPiCS-04 study.
In May, Gilead Sciences announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39111252/gileads-trodelvy-fails-to-hit-primary-goal-in-late-stage-study-with-most-common-type-of-bladder-c" rel="noreferrer noopener">metastatic urothelial cancer (mUC)</a>.
The TROPiCS-04 study evaluated Trodelvy&nbsp;(sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians' choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy.
The study did not meet the primary endpoint of overall survival (OS) in the intention-to-treat (ITT) population.
Trodelvy is the first approved Trop-2-directed antibody-drug conjugate (ADC), which has demonstrated meaningful survival advantages in both 2L+ metastatic TNBC and pre-treated HR+/HER2—metastatic breast cancer.
More than 20 ongoing clinical trials are evaluating Trodelvy as a monotherapy and in combination with other agents&nbsp;across a range of solid tumors, including lung and gynecological cancers.
Trodelvy's is being evaluated in a <a target="_blank" href="https://clinicaltrials.gov/study/NCT05609968" rel="noreferrer noopener">Phase 3</a> EVOKE-03 trial in combination with Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (Pembrolizumab) in PD-L1-high Metastatic Non-small Cell Lung Cancer.
Started in February 2023, the trial is expected to conclude in January 2027.
Price Action: GILD stock is down 0.67% at $86.78 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41405936/spirit-aerosystems-plans-employee-furloughs-amid-ongoing-boeing-strike-faces-layoff-risk" target="_blank" rel="noreferrer noopener">Spirit AeroSystems Plans Employee Furloughs Amid Ongoing Boeing Strike, Faces Layoff Risk</a>.</li>
</ul>

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment

<a href="https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer" title="https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer">https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer</a>

Gilead To Withdraw U.S. Accelerated Approval For Trodelvy In Metastatic Urothelial Cancer After Consultation With FDA; Decision Follows TROPiCS-04 Study Not Meeting Overall Survival Endpoint; Other Trodelvy Indications Remain Unaffected

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average annual return of 12.35%. Currently, Gilead Sciences has a market capitalization of $108.68 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,060.84 today based on a price of $87.29 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729197191_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

BMO Capital analyst Evan Seigerman maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $85 to $94.

BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $94

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital analyst Anthony Chukumba initiated coverage on Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) with a Hold rating and announced a price target of $17. Grocery Outlet shares closed at $16.45 on Wednesday. <a href="https://www.benzinga.com/quote/GO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Aaron Gal initiated coverage on Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with an Outperform rating and announced a price target of $105. Gilead Sciences shares closed at $85.82 on Wednesday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stephens &amp; Co. analyst Jim Salera initiated coverage on First Watch Restaurant Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight rating and announces Price Target of $20. First Watch Restaurant shares closed at $14.77 on Wednesday. <a href="https://www.benzinga.com/quote/FWRG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Sam Eiber initiated coverage on InMode Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMD#NASDAQ">INMD</a>) with a Buy rating and announced a price target of $25. InMode shares closed at $16.65 on Wednesday. <a href="https://www.benzinga.com/quote/INMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy rating and announced a price target of $30. Alumis shares closed at $11.20 on Wednesday. <a href="https://www.benzinga.com/quote/ALMS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GILD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-1024x522.png" alt="" class="wp-image-600656" style="width:638px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17090107/image-149.png 1317w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Initiation

Pre-Market Outlook

ALMS

FWRG

INMD

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Bernstein analyst Aaron Gal initiates coverage on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform rating and announces Price Target of $105.

Bernstein Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $105

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $95 to $100.

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $100

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Government

AMGN

BMRN

REGN

VRTX

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

– Latest Outcomes From HIV Prevention and Treatment Clinical Research, Including Data From Pivotal Phase 3 PURPOSE 1 &amp; 2 Trials –
– Real World Evidence in COVID-19 Reinforce Veklury (remdesivir) as the Antiviral Standard of Care for the Treatment of People Hospitalized for COVID-19 –
– Investigational Obeldesivir Safety and Tolerability Data From BIRCH and OAKTREE Trials Support Continued Evaluation as a Potential Treatment Option for RSV –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced the upcoming presentation of new findings from its antiviral research and development programs at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidweek.org%2F&amp;esheet=54133570&amp;newsitemid=20241008521376&amp;lan=en-US&amp;anchor=IDWeek+2024&amp;index=1&amp;md5=101ec759acb70e35b111d17d3bfbcb58">IDWeek 2024</a>, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead's commitment to helping address the evolving needs of a diverse range of people and communities affected by some of the world's most challenging viruses.

Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Equal-Weight and raises the price target from $76 to $84.

Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $84

Wells Fargo analyst Mohit Bansal upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raises the price target from $78 to $100.

Wells Fargo Upgrades Gilead Sciences to Overweight, Raises Price Target to $100

Plans Regulatory Filings For Lenacapavir As PrEP By End Of 2024; Expanding Access In High-Incidence, Resource-Limited Countries

Gilead Presents PURPOSE 2 Trial Data At HIVR4P Conference Showing Twice-Yearly Lenacapavir Reduced HIV Infections By 96% Among Cisgender Men And Gender-Diverse People

Gilead upgraded to outperform by Leerink on PrEP outlook

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: The striking machinists at Boeing (BA)...

Boeing machinists announce proposal to end strike: Morning Buzz

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $84....

Balanced Outlook on Gilead Sciences Amid Anticipated Anito-cel Trial Results

Morgan Stanley notes that Gilead (GILD) and Arcellx's (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / refractory mult...

Morgan Stanley says anito-cel Phase 2 data next catalyst for Gilead, Arcellx

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry's expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read on…. Today, many diseases still lack effective treatments, mainly because developing new drugs can take years and cost a fortune. But that's changing fast, thanks to the integration of artificial intelligence (AI) and other cutting-edge technologies into biotech research. Experts believe that when properly integrated into research, AI could drastically speed up drug discovery, leading to faster and more effective patient treatments.
Given the industry's positive prospects, it could be ideal to invest in quality biotech stocks such as Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/" target="_blank" rel="noopener">GILD</a>), Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/" target="_blank" rel="noopener">REGN</a>), and Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/" target="_blank" rel="noopener">BIIB</a>), which are set to revolutionize medicine.
The biotechnology sector is buzzing with activity as several biotech firms have gained attention for their groundbreaking research and strong market performance. Moreover, the rising demand for personalized medicine drives the development of tailored treatments based on individual genetic profiles, creating an environment ripe for innovation and expansion.
So far this year, the U.S. Food and Drug Administration (FDA) has <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approved 35 new drugs</a> for conditions such as breast cancer, pulmonary disease, Alzheimer's disease, hypertension, and more. And with more approvals expected before year-end, the sector is poised for even more growth.
The global biotechnology market is projected to hit around $4.61 trillion by 2034, exhibiting a <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20global%20biotechnology%20market%20size%20accounted%20for%20USD%201.55%20trillion,USD%20521.02%20billion%20in%202023.">CAGR of 11.5%</a>. Meanwhile, the U.S. market is expected to reach $830.31 billion by the same year. This growth is propelled by increasing funding, supportive government initiatives, growing industry partnerships, and M&amp;A activities.
In addition, the potential impact of biotech and AI on healthcare is profound. AI can <a href="https://www.forbes.com/councils/forbesbusinesscouncil/2024/06/24/emerging-trends-in-ai-in-biotech/#:~:text=Personalized%20Medicine&amp;text=AI%20algorithms%20are%20central%20to,efficacy%20and%20reducing%20adverse%20effects">revolutionize drug discovery</a> and development by enhancing medical personalization and streamlining complex healthcare data analysis. Generative AI, in particular, is transforming the field by using algorithms to design novel molecules and proteins. The generative AI market in biotech is expected to expand at a<a href="https://www.pharmiweb.com/press-release/2024-04-15/generative-ai-in-biotech-market-to-skyrocket-to-usd-472-million-by-2032-marketresearchbiz#:~:text=Generative%20AI%20in%20Biotech%20utilizes,innovation%20and%20drug%20candidate%20identification."> CAGR of 24.9%</a>, reaching $472 million by 2032.
With that in mind, let's delve into the fundamentals of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, starting with the third choice.
Stock #3: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Its product portfolio includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara solution, and ARCALYST, among other injections.
On September 27, the U.S. Food and Drug Administration (FDA) approved Dupixent&#xAE; (dupilumab) as the first-ever biologic medicine to treat adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
In the same month, the FDA also approved Dupixent as an add-on maintenance treatment for adolescent patients aged 12 to 17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial June 2019 FDA approval for CRSwNP for patients aged 18 years and older.
REGN's net revenues for the second quarter (ended June 2024) increased 12% year-over-year to $3.55 billion. Its non-GAAP net income grew 14.3% from the year-ago value to $1.35 billion, while its income from operations stood at $1.07 billion, up 5.2% year-over-year. The company's non-GAAP net income per share came in at $11.56, representing a 12.9% year-over-year growth.
The consensus revenue estimate of $3.66 billion for the fiscal third quarter (ended September 2024) represents an 8.8% improvement year-over-year. The consensus <a href="https://www.investopedia.com/terms/e/eps.asp">EPS</a> estimate of $11.75 for the to-be-reported quarter represents a 1.4% increase from the same period last year. The company has a promising earnings surprise history, as it surpassed the consensus EPS estimates in three of the trailing four quarters.
Shares of REGN have gained 20.8% over the past year and 15.5% year-to-date.
REGN's<a href="https://stocknews.com/powr-ratings/"> POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has a B grade for Value and Quality. REGN is ranked #10 among 331 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/REGN/">Click here</a> to access additional REGN ratings (Growth, Momentum, Stability, and Sentiment).
Stock #2: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies worldwide for people with serious and complex diseases. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
On August 22, BIIB and Eisai Co., Ltd. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain granted marketing authorization to its Leqembi&#xAE;, the humanized amyloid-beta (Aβ) monoclonal antibody.
In July, BIIB, Beckman Coulter, Inc., and Fujirebio announced a collaboration to potentially identify and develop accessible, minimally invasive blood-based biomarkers specific for tau-pathology in the brain. These tools have the potential to stratify patients or monitor treatment response for a new generation of future therapies impacting tau pathology in Alzheimer's disease.
For the second quarter of 2024, which ended on June 30, BIIB's total revenues increased marginally year-over-year to $2.46 billion. Its non-GAAP total net income attributable for the quarter amounted to $770.90 million or $5.28 per share, representing increases of 31.9% and 31.3%, respectively, from the same period last year.
Per the updated financial guidance for the fiscal year 2024, BIIB now forecasts a non-GAAP EPS between $15.75 and $16.25, up from the previous estimate of $15 and $16.
Street expects BIIB's revenue for the fiscal fourth quarter (ending December 2024) to increase 2.6% year-over-year to $2.45 billion. Its EPS for the same period is expected to register a 16.2% growth from the prior year, settling at $3.43. In addition, it surpassed the EPS estimates in three of the trailing four quarters, which is promising.
However, the stock has declined 2.1% over the past month to close the last trading session at $191.56.
BIIB's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Value and a B for Growth and Sentiment. Within the Biotech industry, it is ranked #6. <a href="https://stocknews.com/stock/BIIB/">Click here</a> to see BIIB's ratings for Momentum, Stability, and Quality.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer. Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On October 02, the company announced that it had signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and sell generic lenacapavir (pending regulatory approval) in 120 countries (mainly low- and lower-middle-income) with high HIV incidence.
These agreements aim to expedite access to lenacapavir for HIV prevention once approved and align with GILD's goal of making HIV prevention accessible globally as part of its mission to end the epidemic.
On September 10, GILD and Genesis Therapeutics announced a strategic partnership to discover and develop new small molecule therapies targeting multiple areas. The collaboration will utilize Genesis' advanced AI platform, GEMS, to design and optimize molecules for targets chosen by Gilead. Both companies will work together on preclinical research, with GILD holding exclusive rights for the clinical development and commercialization of any resulting compounds.
For the fiscal second quarter, which ended on June 30, 2024, GILD's total revenues increased 5.4% year-over-year to $6.95 billion. Its operating income grew 58.8% from the prior year to $2.64 billion, while its non-GAAP net income stood at $2.52 billion, up 49.2% year-over-year. In addition, non-GAAP earnings per share attributable to the company rose 50% from the year-ago value to $2.01.
According to the full-year guidance, GILD forecasts product sales to range from $27.10 billion to $27.50 billion. The company also expects non-GAAP EPS to be between $3.60 and $3.90, an increase from the previous guidance of $3.45 to $3.85.
Analysts expect GILD's revenue for the fiscal years 2024 and 2025 to increase marginally from the prior year, reaching $27.72 billion and $28.02 billion, respectively. Its EPS for the current year is expected to be $3.80 and register a robust year-over-year of 88.6% next year.
Over the past six months, the stock has gained 24.9%, closing the last trading session at $85.05.
It's no surprise that GILD has an overall A rating, equating to a Strong Buy in our POWR Ratings system. It has an A grade for Value and a B for Sentiment and Quality. Of the 331 stocks in the same industry, it is ranked #5.
Beyond what is stated above, we've also rated GILD for Growth, Momentum, and Stability. Get all GILD ratings <a href="https://stocknews.com/stock/GILD/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares were trading at $85.84 per share on Tuesday morning, up $0.79 (+0.93%). Year-to-date, GILD has gained 9.37%, versus a 24.10% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/gild-biib-regn-3-biotech-stocks-set-to-revolutionize-medicine/>3 Biotech Stocks Set to Revolutionize Medicine</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Set to Revolutionize Medicine

There has been a shift in  healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise

My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 12 Buys

IDEAYA reports Phase 1 expansion data for IDE397

Crispr Therapeutics: Poised For A Major Turnaround

AAPL

ABBV

ACLX

AGNC

ALIZF

APLE

ARCC

AVGO

BABA

BASFY

BAYZF

BCSF

BIIB

BLUE

BMWYY

BXSL

CBAUF

CRSP

CSCO

CSWC

FSNUF

GAIN

GLAD

GNTY

GOOD

GOOS

GSBD

HTGC

IDYA

INTC

KVUE

MAIN

MFIC

MSFT

NEWT

NVDA

OBDC

RITM

ROAD

SEMHF

SHEL

SSNLF

STAG

STWD

UNIT

VONOY

Press Releases

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Comments

Gilead Sciences

Interés en corto

Gilead Sciences (NASDAQ:GILD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL